Interleukin-1 Genetic Variations Influence Obesity Effect in Periodontal Disease Progression
Interleukin Genetics Provides New Evidence for Role of IL 1 Genetic Variations in Determining Impact of Obesity on Chronic Inflammatory Diseases WALTHAM, Mass., Aug. 23, 2016 (GLOBE NEWSWIRE) Interleukin Genetics, Inc. (OTCQB ILIU) a life science company focused on the
Interleukin Genetics Provides New Evidence for Role of IL-1
Genetic Variations in Determining Impact of Obesity on Chronic Inflammatory
Mass., Aug. 23, 2016 (GLOBE NEWSWIRE) — Interleukin Genetics, Inc.
(OTCQB:ILIU) a life science company focused on the genetics of chronic
inflammation, today announced the publication of the article “Influence of
Obesity on Periodontitis Progression is Conditional on IL-1 Inflammatory
Genetic Variation” in the Journal
of Periodontology (http://www.joponline.org/doi/abs/10.1902/jop.2016.160408).
The article is the result of a scientific collaboration with key researchers at
Boston University and strongly supports the value of Interleukin-1 (IL-1)
genetics in amplifying the negative impact of obesity.
Genetics continues to build scientific support for the clinical value of IL-1
genetic information,” said Ken Kornman, Chief Scientific Officer. “This study
shows the important role of IL-1 genetic variations in periodontitis
progression in obesity, a growing epidemic worldwide.”
study, which evaluated the influence of IL-1 genetic patterns on periodontal
progression, was conducted on 292 participants from the Department of Veterans
Affairs Dental Longitudinal Study. The analysis found significant interactions
between IL-1 genetic variations and obesity-related traits in predicting
periodontal disease progression. Participants who were both obese and IL-1 test
positive were 70% more likely to experience periodontal disease progression
than those without these risk factors.
study provides further evidence that obese and over-weight patients who are
IL-1 positive will benefit from more intensive dental management,” said Mark B.
Carbeau, Chief Executive Officer of Interleukin Genetics. “Based on these
findings, we are including expanded education and engagement tools for this
high risk population into our product, thus further enhancing value to patients
and employers who offer this expanded benefit.”